DNA Methylation Biomarkers Predict Objective Responses to PD-1/PD-L1 Inhibition Blockade

Immune checkpoint inhibitor (ICI) treatment could bring long-lasting clinical benefits to patients with metastatic cancer. However, only a small proportion of patients respond to PD-1/PD-L1 blockade, so predictive biomarkers are needed. Here, based on DNA methylation profiles and the objective respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, Gang, Cui, Ze-Jia, Zhou, Xiong-Hui, Zhu, Yue-Xing, Chen, Ying, Liang, Feng-Ji, Tang, Da-Nian, Huang, Bing-Yang, Zhang, Hong-Yu, Hu, Zhi-Huang, Yuan, Xi-Yu, Xiong, Jianghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707807/
https://www.ncbi.nlm.nih.gov/pubmed/31475034
http://dx.doi.org/10.3389/fgene.2019.00724

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707807/
https://www.ncbi.nlm.nih.gov/pubmed/31475034
http://dx.doi.org/10.3389/fgene.2019.00724

Ejemplares similares